Promising cocktail targets pancreatic tumors before surgery
NCT ID NCT04940286
First seen Oct 31, 2025 · Last updated Apr 24, 2026 · Updated 30 times
Summary
This study tests a combination of chemotherapy (gemcitabine, nab-paclitaxel) and two immunotherapy drugs (durvalumab, oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to shrink the tumor and improve the body's immune response. About 13 participants will be enrolled to see if this approach helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.